Scholarlink

Background <p>Alopecia areata (AA) is a chronic autoimmune disorder characterized by non-scarring hair loss, which may extend to total scalp (AA totalis) or whole-body hair loss (AA universalis). Nail involvement, though often underestimated, occurs in up to 66% of cases, especially in severe forms and in children.</p> Objective <p>This retrospective study evaluated the efficacy of baricitinib 4 mg/day, a Janus kinase 1/2 inhibitor, in treating nail manifestations associated with severe AA.</p> Methods <p>Thirty-seven patients with very severe AA (Severity of Alopecia Tool [SALT] score &gt; 50) and nail involvement were treated with baricitinib for 48 weeks. Nail changes assessed included trachyonichia, pitting, leukonychia, and others. Clinical assessments were performed at baseline and at 12, 24, 36, and 48&#xa0;weeks using the SALT score, onychoscopy, and the Clinician Reported Outcome (ClinRO) for nail appearance.</p> Results <p>A significant improvement in both hair regrowth and nail abnormalities has been shown. The mean SALT score decreased from 100 to 16.3, and the average number of affected nails reduced from 6.4 to 2.1 (<i>p</i> &lt; 0.001). ClinRO scores also significantly improved (<i>p</i> &lt; 0.001). However, the correlation between hair and nail improvement was weak and not statistically significant (<i>r</i> = 0.15, <i>p</i> = 0.6). This suggests differential responsiveness of hair and nail units.</p> Conclusions <p>The findings support baricitinib as a promising treatment for nail involvement in AA, highlighting the need for routine nail assessment and development of more refined evaluation tools. Limitations include small sample size and lack of long-term data.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness of Baricitinib on Nail Alopecia Areata: A 48-Week Single-Center Retrospective Study

  • 期刊论文

  • 发表日期：

    2026年2月24日

查看全文
  • Michela Starace,
  • Francesca Pampaloni,
  • Federico Quadrelli,
  • Giulia Olivoni,
  • Stephano Cedirian,
  • Luca Rapparini,
  • Francesca Bruni,
  • Bianca Maria Piraccini

摘要

Background

Alopecia areata (AA) is a chronic autoimmune disorder characterized by non-scarring hair loss, which may extend to total scalp (AA totalis) or whole-body hair loss (AA universalis). Nail involvement, though often underestimated, occurs in up to 66% of cases, especially in severe forms and in children.

Objective

This retrospective study evaluated the efficacy of baricitinib 4 mg/day, a Janus kinase 1/2 inhibitor, in treating nail manifestations associated with severe AA.

Methods

Thirty-seven patients with very severe AA (Severity of Alopecia Tool [SALT] score > 50) and nail involvement were treated with baricitinib for 48 weeks. Nail changes assessed included trachyonichia, pitting, leukonychia, and others. Clinical assessments were performed at baseline and at 12, 24, 36, and 48 weeks using the SALT score, onychoscopy, and the Clinician Reported Outcome (ClinRO) for nail appearance.

Results

A significant improvement in both hair regrowth and nail abnormalities has been shown. The mean SALT score decreased from 100 to 16.3, and the average number of affected nails reduced from 6.4 to 2.1 (p < 0.001). ClinRO scores also significantly improved (p < 0.001). However, the correlation between hair and nail improvement was weak and not statistically significant (r = 0.15, p = 0.6). This suggests differential responsiveness of hair and nail units.

Conclusions

The findings support baricitinib as a promising treatment for nail involvement in AA, highlighting the need for routine nail assessment and development of more refined evaluation tools. Limitations include small sample size and lack of long-term data.